A79809
5-氨基水杨酸
95%
别名:
5-AS, 5-氨基-2-羟基苯甲酸, 氨水杨酸
登录 查看组织和合同定价。
选择尺寸
关于此项目
线性分子式:
H2NC6H3-2-(OH)CO2H
化学文摘社编号:
分子量:
153.14
UNSPSC Code:
12352106
NACRES:
NA.22
PubChem Substance ID:
EC Number:
201-919-1
Beilstein/REAXYS Number:
2090421
MDL number:
InChI key
KBOPZPXVLCULAV-UHFFFAOYSA-N
InChI
1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
SMILES string
Nc1ccc(O)c(c1)C(O)=O
assay
95%
form
powder with small lumps
reaction suitability
reaction type: solution phase peptide synthesis
mp
275-280 °C (dec.) (lit.)
application(s)
detection
peptide synthesis
Quality Level
Gene Information
human ... ALOX5(240), PPARG(5468), PTGS1(5742), PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
Application
5-氨基水杨酸是适用于ELISA分析的过氧化物酶底物。这一底物产生可溶性的棕色终产物，可在450nm处通过分光光度法读取。使用3 N NaOH可终止反应并在550 nm处读取结果。
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
target_organs
Respiratory system
存储类别
13 - Non Combustible Solids
wgk
WGK 2
flash_point_f
No data available
flash_point_c
No data available
ppe
dust mask type N95 (US), Eyeshields, Gloves
B Flourié et al.
Alimentary pharmacology & therapeutics, 37(8), 767-775 (2013-03-05)
Aminosalicylates are first-choice treatment for mild-to-moderately active ulcerative colitis (UC); however, multi-dosing regimens are inconvenient. To compare the efficacy and safety of once- (OD) vs. twice- (BD) daily prolonged-release mesalazine (Pentasa, Ferring, Saint-Prex, Switzerland) for active mild-to-moderate UC in a
A Lyakhovich et al.
Alimentary pharmacology & therapeutics, 31(2), 202-209 (2009-11-07)
Mesalazine (mesalamine) (5-ASA) is considered an anti-inflammatory drug for the treatment of inflammatory bowel disease. It is well tolerated by most patients and induces mucosal healing specifically in ulcerative colitis. Besides its anti-inflammatory properties, 5-ASA has been studied for cancer
Alexander C Ford et al.
The American journal of gastroenterology, 106(12), 2070-2077 (2011-09-07)
Maintenance therapy with 5-aminosalicylates (5-ASAs) is recommended in patients with quiescent ulcerative colitis (UC), but compliance rates are low. Once-daily dosing may improve adherence, but impact on the relapse of disease activity is unclear as no previous meta-analysis has studied
Mirjana Rajilić-Stojanović et al.
Inflammatory bowel diseases, 19(3), 481-488 (2013-02-07)
Presence of intestinal microbes is a prerequisite for the development of ulcerative colitis (UC), although deviation of the normal intestinal microbiota composition, dysbiosis, is presumably implicated in the etiology of UC. The fecal microbiota of 30 UC samples obtained from
Christian P Selinger et al.
Inflammatory bowel diseases, 19(10), 2199-2206 (2013-08-01)
Poor adherence frequently impaired the efficacy of therapy to maintain remission from inflammatory bowel diseases (IBD). There is a lack of practical and effective interventions to improve adherence. This study aimed to identify modifiable risk factors, which may yield targets
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持